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Abstract 
Objective. Considering the potential role of lymphocytes in the pathophysiology 
of autism spectrum disorders we aimed to evaluate possible alterations of T-cell 
pools in lymphoid organs of an animal model of autism induced by valproic acid 
(VPA). Pregnant Swiss mice received a single intraperitoneal injection of 600 
mg/kg of VPA (VPA group) or saline (control group) on day 11 of gestation. Male 
animals of the offspring were euthanized on postnatal day 60 for removal of 
thymuses, spleens, and a pool of inguinal, axillary and brachial lymph nodes. 
Cellularity was evaluated, and flow cytometry analysis was performed on cell 
suspensions incubated with mouse antibodies anti-CD3-FITC, anti-CD4-PE and 
anti-CD8-PE-Cy7. We observed that the prenatal exposure to VPA induced a 
reduction in the numbers of CD3+CD4+ T cells in their lymph nodes when 
compared to the control animals. This was rather specific, since it was not seen 
in the thymus or spleen. The consistent decrease in the number of CD4+ T-cells 
in subcutaneous lymph nodes of mice from the animal model of autism may be 
related to the allergic symptoms frequently observed in ASD. Yet, further 
research is necessary to characterize the immunological patterns in ASD and its 
connection with the pathophysiology of this disorder.  
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Autism spectrum disorder (ASD) is a complex developmental condition 
characterized by impairments in social communication and interaction and 
repetitive patterns of behavior and interests [1]. Although its etiology is still 
unknown, both genetic and environmental factors are known to play key roles in 
ASD pathophysiology [2]. Recently, the involvement of the immune system [3] 
and neuroimmune interactions have been proposed as important etiological 
components of ASD [2]. In fact, many immunological alterations are common in 
ASD such as abnormal microglial growth and activation [4], family history of 
autoimmune diseases [5] and abnormal levels of inflammatory cytokines [6]. Also, 
food allergy is frequently present in ASD patients, with early- and late-phase 
reactions, promoting gastrointestinal and skin diseases and asthma [7].  
More specifically, lymphocytic abnormalities were reported in ASD [8], including 
deficiency in CD4+ T-cells. A case-control study including 30 Egyptian children 
(22 boys and 8 girls) with classic-onset autism, revealed that CD4+CD25high 
regulatory T cells are deficient in children with ASD [9]. The authors found the 
frequency of autoimmune diseases among families of the ASD group was 53.3% 
higher than the control group, pointing a familiar autoimmune background. These 
data corroborate with previous studies [5,10,11] and indicate a significant 
association between the reduced number of CD4+CD25high regulatory T cells and 
both allergic manifestations and family history of autoimmunity.  
 Several studies reported abnormalities in T-lymphocytes in about 35% of ASD 
patients with decreased numbers of CD4+ T-cells and increased numbers of 
CD8+ T-cells [12]. Interestingly, in a double-blind study, autistic symptoms were 
diminished in 56% of the patients that were treated with naltrexone, an opiate 
antagonist [13]. This drug increased the number of T-helper inducers and 
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reduced the number of T-cytotoxic suppressors, resulting in a normalization of 
the CD4/CD8 ratio. 
Furthermore, T cells appear to play a key role in many behavioral and cognitive 
processes [14,15], especially in social behavior modulation [16]. For instance, 
immune deficient mice exhibit an impairment in cognition and emotional 
behaviors, which has been attributed specifically to CD4+ T cells [17] Impaired 
learning and memory was reported in severe combined immunodeficiency 
(SCID), Rag1−/−, and Rag2−/− mice (which lack T cells and B cells)[18]. 
Prenatal exposure to valproic acid (VPA) in rodents triggers autistic-like 
morphological and behavioral outcomes [19]. This model has been developed 
based on the fact that maternal use of VPA during pregnancy is associated with 
increased risk of ASD by the children [20].  
Immunological alterations such as thymic atrophy [21] and increased mRNA 
levels of proinflammatory cytokines in the spleen (after LPS challenge) were 
already described in this model [22], but data on the T-cells pools in the thymus 
and secondary lymphoid organs are absent. Here we investigated the status of T 
cell subsets in primary and secondary lymphoid organs, namely thymus, spleen 
and subcutaneous lymph nodes. 
To this purpose, female Swiss mice (obtained from Federal University of Pelotas, 
Pelotas, Brazil) were housed in a 12-h light-dark cycle, with controlled 
temperature (22 ± 1 °C), water and food ad libitum. Pregnancy was determined 
by the presence of vaginal plug, and that was considered the day 0 of gestation. 
On day 11 of gestation pregnant mice received a single intraperitoneal injection 
of 600 mg/kg of VPA (Across Organics, New Jersey, USA) (VPA group) or saline 
(control group). Male animals of the offspring were anesthetized with isoflurane 
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gas and exsanguinated on postnatal day 60. The experimental groups consisted 
of 9 animals per group. The study was approved by the Research Ethics 
Committee of the Clinical Hospital of Porto Alegre (Porto Alegre, Brazil).  
For the cytofluorometric studies, cells from the thymus, spleen and subcutaneous 
lymph nodes (inguinal, axillary and brachial chains) were obtained after 
homogenizing the tissues with a tissue grinder and counted in Neubauer 
chambers. Suspensions containing 106 cells were prepared, and incubated with 
fluorochrome-labeled rat anti-mouse antibodies anti-CD3-FITC (1:50), anti-CD4-
PE (1:50) and anti-CD8-PE-Cy7 (1:100) (BD Biosciences, San Jose, USA) for 20 
min with 2% fetal bovine serum-PBS solution for 20 min at 4°C. Cells were then 
washed and analyzed by flow cytometry using the Attune® Acoustic Focusing 
Cytometer (Applied Biosystems, CA, USA), equipped with the Attune® 
Cytometric Software version 1.2.5. 
Data were statistically analyzed using SPSS for Windows (SPSS Inc., Chicago, 
Ill., USA) and graphs were plotted with GraphPad Prism software. Results were 
expressed as means ± standard error (SE) and statistical comparisons were 
performed using   multiple t-tests followed by Bonferroni correction. Samples 
were considered statistically different when p value was ≤0.05. 
Prenatal exposure to valproic acid decreases CD4+ T lymphocytes in 
subcutaneous lymph nodes of offspring  
We first noticed that no differences between groups were found in terms lymphoid 
organ weight (Table 1). Moreover, no differences were observed in both immature 
(CD4-CD8- and CD4+CD8+), as well as mature (CD3+CD4+ CD8- or CD3+CD4-
CD8+ T-cell subsets in the thymus (Table 1). Similarly, no differences were found 
in spleen-derived T cell subsets (Table 1). Interestingly however, in 
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subcutaneous lymph nodes, the numbers of CD3+CD4+ T cell subset were 
significantly reduced in VPA group (Figure 1B), whereas the corresponding 
percentage was increased (Figure 1C). The membrane density of CD3, CD4 and 
CD8, as ascertained by median fluorescent intensity (MFI) on T lymphocytes did 
not significantly differ between VPA and control groups (Supplementary Figure 
S1) 
Considering that the etiology of ASD remains unknown, the association between 
this disorder and immunological disturbances is becoming more evident [3]. 
However, to date, it has not been elucidated whether immune disorders are 
causative of ASD or if ASD leads to immune alterations. Recently, more attention 
has been given to the postnatal immune imbalance of specific immune cell 
subsets, including CD4+ and CD8+ T cells. Reduced number of T cells in 
individuals with ASD, as well as an altered CD4+/CD8+ T-cell ratio was reported 
in 1986 [23] and in the following years abnormalities such as increased TNFα and 
decreased IL-10 production by T-cells, increased production of IL-17 [6,24], 
reduction of peripheral CD4+ [8] and dysregulation of Th1/Th2/Th17 T-cell pools 
[25] were all described in children with ASD. 
Reports of allergic manifestations among individuals with ASD are common. For 
instance, experience of atopic diseases in early childhood was associated with a 
3.40-fold increased risk of ASD [26]. In addition, higher frequency of atopic 
dermatitis, asthma, rhinitis and serum IgE have been demonstrated in children 
with Asperger compared to age-matched controls (87% vs. 7%) [27].  
Exposure to VPA may lead to impairments in the proliferative process of 
lymphocytes in vitro [28], as well as to a drastic reduction in the number of these 
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cells in lymph nodes, spleen and peripheral blood [29].  Furthermore, rats 
exposed prenatally to VPA display thymic atrophy [21].  
An important aspect to be considered is the crosstalk between the mother and 
the embryo. In light of the neuroimmune influence on ASD pathophysiology and 
the in vitro effect of VPA on lymphocytes, we conceive that the maternal blood 
cells might be influenced by VPA, even upon a single injection protocol. 
Accordingly, the mother immune response could influence the neuroimmune 
system in the embryo, like a fingerprint, interfering in the neurodevelopment later 
on. This hypothesis, associated to epigenetic changes could explain how a single 
injection of VPA i.p. during pregnancy is capable to trigger behavioral-like autism 
in the offspring, with anatomic and molecular alterations in the nervous and 
immune systems through life. In the present work, no difference was found 
between thymuses weight and cellularity in mice from VPA and control groups. 
The discrepancy between those results can be ascribed to differences in the 
animal species studied and to the use of animals twice old as those reported by 
Schneider et al. [21].   
Given the large amount of data supporting the role of immune responses in ASD, 
advances in deciphering the functional interplay between immune cells and ASD 
symptoms will likely provide vital insights into the mechanisms and potential 
therapy of neurodevelopmental disorders.  
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Figure legend 
 
Figure 1. Mice from the VPA model of autism present reduced numbers of 
CD3+CD4+ T-cells in subcutaneous lymph nodes. A) Representative FACS 
plots. B) Absolute number of T lymphocytes (x106). C) Percentage of T 
lymphocytes. Data are presented as means ± standard error, with nine animals 
being analyzed per group.  
 
Figure S1. The membrane density of CD3, CD4 and CD8, as shown through 
the corresponding median fluorescent intensity (MFI) on T lymphocytes, is 
not significantly altered in mouse subcutaneous lymph nodes, in the VPA 
model of autism. Data are presented as means ± standard error, with four 
animals being analyzed per group. 
